焦兰晨,王可铮.PET/CT预测非小细胞肺癌PD-1/PD-L1表达及免疫治疗评估中的价值[J].中国肿瘤,2022,31(8):672-678.
PET/CT预测非小细胞肺癌PD-1/PD-L1表达及免疫治疗评估中的价值
The Value of PET/CT to Predict PD-1/PD-L1 Expression and Assess Immunotherapy in Non-small Cell Lung Cancer
投稿时间:2022-03-30  
DOI:10.11735/j.issn.1004-0242.2022.08.A008
中文关键词:  PET/CT  非小细胞肺癌  PD-1/PD-L1  免疫治疗
英文关键词:PET/CT  non-small cell lung cancer  PD-1/PD-L1  immunotherapy
基金项目:
作者单位
焦兰晨 哈尔滨医科大学附属肿瘤医院 
王可铮 哈尔滨医科大学附属肿瘤医院 
摘要点击次数: 483
全文下载次数: 134
中文摘要:
      摘 要:非小细胞肺癌 (non-small cell lung cancer,NSCLC)约占肺癌的80%~90%,其预后较差,传统治疗方法如手术切除、放化疗对于晚期患者疗效有限。免疫治疗作为一种新兴靶向治疗手段,能有效提高晚期NSCLC患者的预后和生存期,但该治疗方法常仅在以PD-1/PD-L1为代表的免疫检查点阳性患者才能受益。而PET/CT作为一种全身显像方式,可以综合评价全身各处肿瘤的生物学信息。全文旨在对PET/CT预测肿瘤PD-1/PD-L1表达及评估免疫治疗预后方面的价值进行综述。
英文摘要:
      Abstract: Non-small cell lung cancer(NSCLC) accounts for about 80%~90% of lung cancers and has a poor prognosis. Conventional therapies such as surgical resection, radiotherapy and chemotherapy have limited efficacy for patients in the progressive stage. As an emerging targeted therapy, immunotherapy can effectively improve the prognosis and survival of patients with advanced NSCLC. However, immunotherapy often benefits only patients with immune checkpoint-positive, such as PD-1/PD-L1. PET/CT, as a whole-body imaging modality, can comprehensively evaluate the biological information of tumors throughout the body. This article aims to review the value of PET/CT in predicting PD-1/PD-L1 expression and assessing the prognosis of immunotherapy.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器